Silybin supplementation during HCV therapy with pegylated interferon-a plus ribavirin reduces depression and anxiety and increases work ability

Giulia Malaguarnera, Gaetano Bertino, Giuseppe Chisari, Massimo Motta, Michele Vecchio, Marco Vacante, Filippo Caraci, Carmela Greco, Filippo Drago, Giuseppe Nunnari, Michele Malaguarnera

Research output: Contribution to journalReview article

Abstract

Background: Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associated with work ability in subjects with chronic hepatitis C treated with Pegylated-Interferon-a2b (Peg-IFN) and Ribavirin (RBV). Methods: Thirty-one patients (Group A) with chronic hepatitis and other 31 subjects in Group B were recruited in a randomized, prospective, placebo controlled, double blind clinical trial. Group A received 1.5 mg/kg per week of Peg-IFN plus RBV and placebo, while Group B received the same dosage of Peg-IFN plus RBV plus association of Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg in pills for 12 months. All subjects underwent to laboratory exams and questionnaires to evaluate depression (Beck Depression Inventory - BDI), anxiety (State-trait anxiety inventory - STAI) and work ability (Work ability Index - WAI). Results: The comparison between group A and group B showed significant differences after 6 months in ALT (P < 0.001), and viremia (P < 0.05), after 12 months in ALT (P < 0.001), and AST (P < 0.001), at follow up in AST (P < 0.05), and ALT (P < 0.001). Significant difference were observed after 1 month in WAI (p < 0.001) and BDI (P < 0.05), after 6 months in WAI (P < 0.05) and STAI (P < 0.05), after 12 months and at follow up in WAI, STAI and BDI (p < 0.01). Conclusions: The supplementation with Silybin-vitamin E -phospholipids complex increased work ability and reduced depression and anxiety in patients treated with Peg-IFN and RBV.

Original languageEnglish
Article number398
JournalBMC Psychiatry
Volume16
Issue number1
DOIs
Publication statusE-pub ahead of print - 2017

    Fingerprint

Keywords

  • Anxiety
  • Depression
  • Hepatitis C
  • Interferon
  • Silybin
  • Work ability index

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Malaguarnera, G., Bertino, G., Chisari, G., Motta, M., Vecchio, M., Vacante, M., Caraci, F., Greco, C., Drago, F., Nunnari, G., & Malaguarnera, M. (2017). Silybin supplementation during HCV therapy with pegylated interferon-a plus ribavirin reduces depression and anxiety and increases work ability. BMC Psychiatry, 16(1), [398]. https://doi.org/10.1186/s12888-016-1115-z